Valuation: Intervacc AB

Market Cap 453M 47M 41.09M 37.76M 35.19M 66.75M 4.47B 67.77M 176M 2.2B 176M 173M 7.58B P/E 2026 *
-6.05x
P/E 2027 * -6.05x
Enterprise Value 360M 37.35M 32.66M 30.01M 27.97M 53.06M 3.56B 53.86M 140M 1.75B 140M 137M 6.02B EV / Sales 2026 *
20.4x
EV / Sales 2027 * 13x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Director/Board Member 68 2024-12-31
Director/Board Member 72 2023-12-31
Director/Board Member 71 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.87%+8.57%+54.24%+147.40% 27.28B
Weighted average by Cap. +2.46%+6.47%+58.32%+136.98%

Financials

2026 *2027 *
Net sales 17.7M 1.84M 1.6M 1.47M 1.37M 2.61M 175M 2.65M 6.88M 85.89M 6.89M 6.74M 296M 30.05M 3.12M 2.72M 2.5M 2.33M 4.43M 297M 4.49M 11.68M 146M 11.69M 11.44M 502M
Net income -80.8M -8.38M -7.32M -6.73M -6.27M -11.9M -798M -12.08M -31.41M -392M -31.45M -30.77M -1.35B -83.65M -8.67M -7.58M -6.97M -6.49M -12.32M -826M -12.51M -32.52M -406M -32.56M -31.86M -1.4B
Net Debt -93M -9.64M -8.43M -7.75M -7.22M -13.7M -918M -13.9M -36.15M -451M -36.19M -35.42M -1.56B -63M -6.53M -5.71M -5.25M -4.89M -9.28M -622M -9.42M -24.49M -306M -24.52M -23.99M -1.05B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
-